🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05136209
Recruiting Not applicable

Comparison of Posterior Continuous Curvilinear Capsulorhexis With or Without Anterior Vitrectomy

NCT05136209 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-sen University
Phase
Not applicable
Started
2021-11-01
Last updated
2021-11-29

Condition(s) studied

Congenital Cataract

Investigational drug(s) / intervention(s)

PCCC procedure without A-vitPCCC+A-Vit procedure

PCCC procedure without A-vit: In this randomized clinical trial, patients receive cataract surgery on both eyes on the same day. For each patient, one eye is randomly assigned to undergo PCCC+A-Vit procedure, while the fellow eye is undergoing PCCC procedure without A-Vit.

PCCC+A-Vit procedure: PCCC+A-Vit procedure

Study summary

Selecting the appropriate surgical approach for congenital cataracts presents challenging for ophthalmologists. This prospective, randomized controlled study aims to compare the prognosis of posterior continuous curvilinear capsulorhexis (PCCC) with or without anterior vitrectomy (A-Vit) in treating congenital cataracts.

Eligibility

Sex
ALL
Min age
1 Month
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Children with bilateral congenital cataracts without other ocular abnormalities * Gestational age at birth \>37 weeks * No more than 18 years old * Pupils could dilate normally pre-operation * Have signed a consent form * Can be followed Exclusion Criteria: * Intraocular pressure \>21 mmHg * History of ocular trauma and intraocular surgery

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong Recruiting

More Sun Yat-sen University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05136209 on ClinicalTrials.gov ↗ ← All trials in China